Osteoporosis therapy - A pluralistic approach;Osteoporose-therapie - Ein pluralistischer ansatz

Internist

Volumn 39, Issue 12, 1998, Pages 1253-1263

  Lehmann, R ^b   Allolio, B ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; ESTRADIOL; ETIDRONIC ACID; FLUORIDE; FLUORIDE SODIUM; FLUOROPHOSPHATE; RALOXIFENE; VITAMIN D;

OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

CALCITONIN; CALCIUM, DIETARY; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; FEMALE; FLUORIDES; FRACTURES, SPONTANEOUS; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; VITAMIN D;

EID: 0032445471     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050298     Document Type: Review

References (95)

1. Adami S, Zamberlan N (1996) Adverse effects of bisphosphonates. Drug Safety 14:158-170
2. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan DJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU (1994) Raloxifene (LY139481) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
3. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Markus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, for the Fracture Intervention Trial Group (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
4. Bottermann P (1994) Moderne Behandlung der primären Osteoporose. Internist 35:1105-1116
5. Bryant HU, Dere WH (1998) Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc Soc Exp Biol Med 217:45-51
6. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR, for the Study of Osteoporotic Fractures Research Group (1995) Estrogen replacement therapy and fractures in older women. Ann Intern Med 122:9-16
7. 3 and Calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637-1642
8. Chesnut C, Baylink DJ, Doyle D, Genant H, Harris S, Kiel DP, LeBoff M, Stock JL, Gimona A, Andriano K, Richardson P for the "Proof" study group (1998) Salmon-calcitonin nasal spray prevents vertebral fractures in established osteoporosis. Further interim results of the "Proof" study. Osteoporosis Int 8 [Suppl 3]:13
9. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:158-1593
10. Cumming RG, Nevitt MC (1997) Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 12:1321-1329
11. Cummings SR, Black DM, Nevitt MC, Brownwer W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM, for the Study of Osteoporotic Fractures Research Group (1993) Bone density at various sites for prediction of hip fractures. Lancet 341:72-75
12. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM, for the Study of Osteoporotic Fractures Research Group (1995) Risk factors for the hip fracture in white women. N Engl J Med 332:767-773
13. Dambacher MA, Haas HG, Rüegsegger P (1991) Pathophysiologie der Osteoporose und Knochendichtebestimmung. Internist 32:63-69
14. Dambacher MA, Schacht E (1998) Aktive Vitamin D-Metabolite (D-Hormone) in der Osteoporose-Therapie auf der Basis neuer Erkenntnisse zur Pathogenese. Osteologie 7:5-25
15. Dawson-Hughes B, Dallai GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S (1990) A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 323:878-883
16. Dawson-Hughes B, Harris SS, Krall EA, Dallai GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670-676
17. De Groen PC, Lubbe DF, Hirsch U, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1541
18. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647
19. Dören M (1996) Selektive Östrogenrezeptoren - neue Möglichkeiten der Osteoporoseprophylaxe und -therapie? Med Klin 91 [Suppl 1]:44-45
20. Eastell R (1998) Treatment of postmenopausal osteoporosis. N Engl J Med 338:736-746
21. Elders PJM, Netelenbos JC, Lips P, van Ginkel FC, Khoe E, Leeuwenkamp OR, Hackeng WHL, van der Stell PF (1991) Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age. J Clin Endocrinol Metab 73:533-540
22. Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB, for the Fracture Intervention Trial Research Group (1997) Treatment with alendronate prevents fractures in women at highest risk. Arch Intern Med 157:2617-2624
23. Ettinger B, Genant HK, Cann CE (1985) Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 102:319-324
24. Ettinger B, Genant HK, Cann CE (1987) Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 106:40-45
25. Ettinger B, Black D, Cummings S, Genant H, Glüer C, Lips P, Knickerbocker R, Eckert S, Nickelsen T, Mitlak, for the MORE Study Group (1998) Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses. Osteoporosis Int 8[Suppl 3]:11
26. Farley JR, Wergedal JE, Baylink DJ (1983) Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science 222:330-332
27. Fitzpatrick LA, Coleman DT, Bilezikian JP (1992) The target tissue actions of parathyroid hormone. In:Coe FL, Favus MJ (Hrsg) Disorders of bone and mineral metabolism. Raven Press, New York, S 123-148
28. Francis RM (1995) Oral bisphosphonates in the treatment of osteoporosis: a review. Curr Ther Res 56:831-851
29. Gennari C, Agnusdei D, Camporeale A (1993) Longterm treatment with calcitonin in osteoporosis. Horm Metab Res 25:484-485
30. Gutin B, Kasper MJ (1992) Can vigorous exercise play a role in osteoporosis prevention? A review. Osteoporosis Int 2:55-69
31. Garnero P, Gineyts E, Riou JP, Delmas PD (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785
32. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11337-349
33. Garnero P, Borel O, Grant SFA, Ralston SH, Delmas PD (1998) Collagen 1α1 Sp1 Polymorphism, bone mass, and bone turnover in healthy French premenopausal women: the OFELY study. J Bone Miner Res 13:813-817
34. Gennari C, Chierichetti SM, Bigazzi S, Furi L, Gonnelli S, Zacchei F (1985) Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 38:455-464
35. Gonza Lez D, Ghiringhelli G, Mautalen C (1986) Acute antiosteoclastic effect of salmon calcitonin in osteoporotic women. Calcif Tiss Int 38:71-75
36. Grauer A, Abendroth K, Heller M, Kruse HP, Minne HW, Ringe JD, Sabo D, Schulz A, Semler J (1998) Der Morbus Paget des Knochens. Epidemiologie, Diagnostik und Vorschläge für die Therapie. Dt Ärztebl 95:2021-2026
37. Hamdy RC (1995) Clinical features and pharmacologic treatment of Paget's disease. Endocrinol Metab Clin North Am 24:421-436
38. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Miller PD, Licata AA, Chesnut CH (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three year of blinded therapy followed by one year of open therapy. Am J Med 95:557-567
39. Heaney RP (1993) Thinking straight about calcium. N Engl J Med 328:503-505
40. Hesch RD, Minne HW, Ringe JD, Seif F, Ziegler R (1988) Nomenklatur der Osteoporose. Endokrinologie Informationen 12:69-70
41. Hesch RD, Rittinghaus EF (1991) Abschließende Bewertung der Osteoporosetherapie mit Fluoriden. Internist 32:708-720
42. Hosking D, Chilvers CED, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ, for the Early Postmenopausal Intervention Cohort Study Group (1998) Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 338:485-492
43. Hüfner M (1996) Östrogene in der Menopause - Therapie und Prophylaxe. II. Östrogene und Osteoporose. Internist 37:405-409
44. Jakob F (1997) Bisphosphonate: Pharmakologie und molekulare Wirkprinzipien. Klinikarzt 26:131-135
45. Johannes CB, Crawford SI, Posner JG, McKinley SM (1994) Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. Am J Epidemiol 140:539-452
46. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137-1141
47. Kanis JA (1995) Treatment of symptomatic osteoporosis with fluoride. Am J Med 95:S53-S61
48. Kleerekoper M, Mendlovic DB (1993) Sodium fluoride therapie of postmenopausal osteoporosis. Endocr Rev 14:312-323
49. Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbol I, Mauridsen HT (1994) Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 12:992-997
50. Lehmann R, Allolio B (1995) Epidemiologie der Osteoporose. Therapiewoche 23:1351-1356
51. Liberman UA, Weiss SR, Bröll J, Minne HM, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch U, Karpf DB, for the Aledronate Phase III Osteoporosis Treatment Study Group (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
52. Lips P (1996) Vitamin D deficiency and osteoporosis: the role of vitamin D deficiency and treatment with vitamin D and analogues in the prevention of osteoprosis-related fractures. Eur J Clin Invest 26:436-442
53. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ (1994) Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154:2485-2488
54. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ (1994) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Nat Canc Int 86:1534-1539
55. Lufkin EG, Wahner HW, O'Fallon WM, Hoggson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL (1992) Treatment of postmenopausal osteoprosis with transdermal estrogen. Ann Intern Med 117:1-9
56. Lufkin EG, Argueta R, Whitker MD, Cameron AL, Hong VH, Egan KS, O'Fallon WM, Riggs BL (1994) Pamidronate: an unrecognized problem in gastrointestinal tolerabilty. Osteoporosis Int 4:320-322
57. Maresca V (1985) Human calcitonin in the management of osteoporosis: a multicenter study. J Int Med Res 13:311-316
58. Mazzuoli GF, Passeri M, Gennari Minisola S, Antonelli R, Valtora C, Palmmeri E, Cervellin GF, Gonnelli S, Francini G (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3-8
59. Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P, Loeb G, Rouillon A, Barry S, Evreux JC, Avouac B, Marchandise X, and the FAVOStudy group (1998) Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporosis Int 8:4-12
60. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA (1994) Prediction of bone density from vitamin D receptor alleles. Nature 367:284-287
61. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370-376
62. Ott SM, Woodson GC, Huffer WE, Miller PD, Watts NB (1994) Bone histomorphometric changes after cyclic therapy with phosphate and etidronate sodium in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 78:968-972
63. Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effects of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 305:556-561
64. Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, McCracken R, Avioli LV (1991) Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Nat Acad Sci 88:5134-5138
65. Pak CY Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR (1995) Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 123:401-408
66. Pfeilschifter J (1997) Diagnostik der Osteoprose. Klinikarzt 26:115-121
67. Raue F, Grauer A (1994) Bisphosphonate, ein neues Therapieprinzip bei Knochenstoffwechselerkrankungen. Med Klin 89:421-428
68. Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli G, Taquet AN, Setnikar I, Collette J, Gosset C (1998) The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. Ann Intern Med 129:1-8
69. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ (1995) Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women -a randomized controlled trial. Am J Med 98:331-335
70. Reincke M, Allolio B (1996) Östrogene in der Menopause - Therapie und Prophylaxe. III. Östrogensubstitution in der Menopause: Nutzen und Risiken bei der Prävention und Therapie kardiovaskulärer Erkrankungen. Internist 37:410-415
71. Rico H, Revilla M, Hernandez ER, Villa LF, Alvarez de Buergo M (1995) Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 56:181-185
72. Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton LJ III (1990) Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809
73. Riggs BL, Khosla S, Melton LJ III (1998) A unitary model for involutional osteoporosis. Estrogen deficiency causes both type I and type II osteoprosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763-773
74. Ringe JD (1989) Treatment of primary osteoporsis with calcium and different dosages of salmon calcitonin. J Bone Miner Res 4 [Suppl 1]:1018
75. Ringe JD (1991) Therapie der Osteoporose mit Fluoriden und Kalzitoninen. Internist 32:80-89
76. Ringe JD (1993) Progressionshemmung bei Verminderung der Knochenmasse und manifester Osteoporose. Internist 34:300-306
77. Riis B, Thomsen K, Christiansen C (1987) Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N Engl J Med 316:173-177
78. Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692-2696
79. Schacht E (1996) Basis der Osteoporose-therapie mit aktiven Vitamin-D-Metaboliten. Med Klin 91 [Suppl 1]:34-37
80. Scharla SH, Ziegler R (1994) Bedeutung des Vitamin O und seiner Metaboliten in der Pathogenese und Therapie der Osteoporose. Dtsch Med Wschr 119:847-851
81. Schneider DL, Barrett-Connor EL, Morton DJ (1997) Timing of postmenopausal estrogen for optimal bone mineral density. JAMA 277:543-547
82. Storm T, Thamsborg G, Genant HK, Steiniche T, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271
83. Storm T, Kollerup G, Thamsborg G, Genant HK, Sorensen OH (1996) Five years clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 23:1560-1564
84. Tilyard MW, Spears GFS, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357-362
85. Turner CH, Sato M, Bryant HU (1994) Raloxifene preserves bone strenght and bone mass in ovariectomized rats. Endocrinology 135:2001-2005
86. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445-1451
87. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79
88. Willing M, Sowers M, Aron D, Clark MK, Burns T, Bunten C, Crutchfield M, D'Agostino D, Jannausch M (1998) Bone mineral density and its change in white women: estrogen and vitamin D receptor genotypes and their interaction. J Bone Miner Res 13:695-705
89. Wimalawansa SJ (1995) Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 99:36-42
90. Wüster C, Schurr W, Scharla S, Raue F, Minne HW, Ziegler R (1991) Superior tolerability of human versus salmon calcitonin preparations in young healthy volunteers. J Eur Clin Pharmacol 41:211-215
91. Wuttke W (1996) Östrogene in der Menopause - Therapie und Prophylaxe. I. Hormonsubstitution im Klimakterium und in der Postmenopause. Internist 37:402-404
92. Ziegler R (1990) Was ist gesichert in der Therapie der Osteoporose? Internist 31:680-688
93. Ziegler R (1991 ) Osteoporosetherapie nach dem ADFR-Schema (insbesondere mit Parathormon bzw. Etidronat). Internist 32:76-79
94. Ziegler R (1993) Was ist gesichert in der Behandlung der Osteoporose der Frau in der Menopause? Internist 34:18-24
95. Ziegler R (1996) Osteoporose - Diagnose und Therapie. Med Klin 91 [Suppl 1]:29-33